Zydus Lifesciences saw its shares jump more than 6% following the release of its first-quarter financial results, with the company's India business emerging as the primary growth engine.

The Ahmedabad-based pharmaceutical company, formerly known as Cadila Healthcare, reported its Q1 performance with India formulations leading overall growth. India's domestic pharmaceutical market has been expanding steadily, driven by increasing healthcare access, chronic disease prevalence, and rising demand across tier-2 and tier-3 cities, making it a critical revenue pillar for major Indian drugmakers. Zydus Lifesciences is listed on the National Stock Exchange of India under the ticker ZYDUSLIFE.

In North America, formulations sales for the quarter stood at ₹3,098 crore. This represented a year-over-year decline of 2.6% but a sequential improvement of 4.9% compared to the preceding quarter. The company attributed the sequential recovery to sustained volume expansion and new product launches in the market. Indian pharmaceutical companies have broadly faced pricing pressure in the US generics market, and sequential improvement metrics are closely watched as indicators of stabilizing demand in that segment.

Zydus Lifesciences operates across multiple geographies including India, the United States, and emerging markets, with a portfolio spanning various therapeutic categories. The company is part of the Zydus group, one of India's leading healthcare and pharmaceutical conglomerates.

The market response to the results was positive, with the stock gaining over 6% in trading following the announcement.

Source: CNBC-TV18 Markets